<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Pancreatic β-cell proliferation is infrequent in adult humans and is not increased in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> despite <z:hpo ids='HP_0001513'>obesity</z:hpo> and <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, suggesting the existence of inhibitory factors </plain></SENT>
<SENT sid="1" pm="."><plain>Free fatty acids (FFAs) may influence proliferation </plain></SENT>
<SENT sid="2" pm="."><plain>In order to test whether FFAs restrict β-cell proliferation in vivo, mice were intravenously infused with saline, Liposyn II, <z:chebi fb="105" ids="17234">glucose</z:chebi>, or both, continuously for 4 days </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="23" ids="18059">Lipid</z:chebi> infusion did not alter basal β-cell proliferation, but blocked <z:chebi fb="105" ids="17234">glucose</z:chebi>-stimulated proliferation, without inducing excess β-cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>In vitro exposure to FFAs inhibited proliferation in both primary mouse β-cells and in rat <z:e sem="disease" ids="C0021670" disease_type="Neoplastic Process" abbrv="">insulinoma</z:e> (INS-1) cells, indicating a direct effect on β-cells </plain></SENT>
<SENT sid="5" pm="."><plain>Two of the fatty acids present in Liposyn II, <z:chebi fb="0" ids="17351">linoleic acid</z:chebi> and <z:chebi fb="0" ids="15756">palmitic acid</z:chebi>, both reduced proliferation </plain></SENT>
<SENT sid="6" pm="."><plain>FFAs did not interfere with cyclin D2 induction or nuclear localization by <z:chebi fb="105" ids="17234">glucose</z:chebi>, but increased expression of inhibitor of cyclin dependent kinase 4 (INK4) family cell cycle inhibitors p16 and p18 </plain></SENT>
<SENT sid="7" pm="."><plain>Knockdown of either p16 or p18 rescued the antiproliferative effect of FFAs </plain></SENT>
<SENT sid="8" pm="."><plain>These data provide evidence for a novel antiproliferative form of β-cell glucolipotoxicity: FFAs restrain <z:chebi fb="105" ids="17234">glucose</z:chebi>-stimulated β-cell proliferation in vivo and in vitro through cell cycle inhibitors p16 and p18 </plain></SENT>
<SENT sid="9" pm="."><plain>If FFAs reduce proliferation induced by <z:hpo ids='HP_0001513'>obesity</z:hpo> and <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, targeting this pathway may lead to new treatment approaches to prevent <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>